Telix Pharmaceuticals Doses First Patient in Phase 3 Trial of TLX101-Tx for Recurrent Glioblastoma

Key Takeaways

• TLX101-Tx becomes the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, an aggressive brain cancer
• The IPAX-BrIGHT trial represents a potentially breakthrough approach for patients with recurrent glioblastoma who have extremely limited treatment options
• First patient dosed at Austin Health in Melbourne under Professor Hui Gan’s supervision, launching pivotal trial that could reshape glioblastoma treatment

---

Historic Milestone in Brain Cancer Treatment

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has achieved a significant milestone in oncology by dosing the first patient with TLX101-Tx (¹³¹I-iodofalan) in their pivotal Phase 3 IPAX-BrIGHT trial on April 15, 2026. This marks a historic moment as the first radiopharmaceutical therapy to advance to Phase 3 development for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for oncology - brain cancer, with TLX101-Tx and ¹³¹I-iodofalan most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Revolutionary Approach to Glioblastoma Treatment

The patient was treated at Austin Health in Melbourne, Australia, under the supervision of Professor Hui Gan, marking the beginning of what could be a paradigm shift in glioblastoma treatment. Glioblastoma affects approximately 12,000-15,000 patients annually in the United States alone, with a median survival of just 12-18 months despite aggressive treatment.

TLX101-Tx represents a novel radiopharmaceutical approach using iodine-131 isotope technology. Unlike conventional chemotherapy or radiation therapy, this targeted radiopharmaceutical is designed to deliver precise radiation directly to cancer cells while potentially minimizing damage to healthy brain tissue.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Competitive Landscape

This development positions Telix ahead of established competitors including Novocure (Optune), Bristol Myers Squibb (Opdivo), Merck (Keytruda), and Roche (Avastin) in the glioblastoma treatment space. The radiopharmaceutical approach could offer significant advantages over current standard-of-care treatments, which have shown limited efficacy in this challenging indication.

The IPAX-BrIGHT trial specifically targets patients with recurrent glioblastoma, a population with particularly poor prognosis and few viable treatment options. Current treatments for recurrent glioblastoma include repeat surgery, re-irradiation, and various chemotherapy regimens, but response rates remain disappointingly low.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for oncology - brain cancer pricing, access, and launch sequencing.

Clinical and Regulatory Implications

Telix’s advancement to Phase 3 represents years of preclinical and early-phase clinical development. The company’s expertise in radiopharmaceuticals, demonstrated through their existing portfolio of diagnostic and therapeutic agents, provides a strong foundation for this ambitious program.

The radiopharmaceutical market has experienced significant growth, with several recent FDA approvals validating the therapeutic potential of targeted radioligand therapies. TLX101-Tx’s unique mechanism of action could potentially overcome some of the traditional challenges in glioblastoma treatment, including the blood-brain barrier and tumor heterogeneity.

IntelligenceStrategic Takeaways▾

TLX101-Tx becomes the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, an aggressive brain cancer The IPAX-BrIGHT trial represents a potentially breakthrough approach for patients with recurrent glioblastoma who have extremely limited treatment options First patient dosed at Austin Health in Melbourne under Professor Hui Gan’s supervision, launching pivotal trial that could reshape glioblastoma treatment

Looking Forward

The Phase 3 trial will evaluate TLX101-Tx’s efficacy and safety compared to standard-of-care treatment in patients with recurrent glioblastoma. Success in this trial could lead to regulatory submissions and potentially transform treatment options for thousands of patients worldwide facing this devastating diagnosis.

For Telix Pharmaceuticals, this milestone represents validation of their radiopharmaceutical platform and positions the company as a potential leader in precision oncology. The trial’s progress will be closely watched by the oncology community, given the significant unmet medical need in glioblastoma treatment.

---

Frequently Asked Questions

What does this mean for glioblastoma patients?

This represents the first radiopharmaceutical therapy to reach Phase 3 trials for glioblastoma, offering a potentially new treatment approach for patients with recurrent disease who currently have very limited options and poor prognosis.

When will TLX101-Tx be available to patients?

TLX101-Tx is currently in Phase 3 trials, which typically take 2-4 years to complete. If successful, regulatory review could take an additional 6-12 months, meaning potential availability could be 3-5 years away, assuming positive trial results.

How does TLX101-Tx differ from current glioblastoma treatments?

Unlike conventional chemotherapy or external radiation, TLX101-Tx is a radiopharmaceutical that delivers targeted radiation directly to cancer cells using iodine-131 isotope technology, potentially offering more precise treatment with fewer side effects to healthy brain tissue.

Related coverage

• Orion Pharma's ODM-212 Shows Favorable Safety in Phase 1/2 TEADES Trial for Advanced Solid Tumours
• Risen Pharma Initiates Phase 2 Trial for RP902 in Alzheimer's
• GlycoNex Secures PMDA Approval for GNX1021 Phase I Trial